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REGULATION OF THE PRODUCTION 
OF PRO-INFLAMMATORY CYTOKINES 
AND ANTAGONISTS DURING 
CHEMOTHERAPY-INDUCED NEUTROPENIA 
IN PATIENTS WITH HAEMATOLOGICAL 
MALIGNANCIES*
Nathalie E. J. Denecker,1 Bart-Jan Kullberg,' Joost P. H. Drenth,
John M. M. Raemaekers,2 Jos W. M. Van Der Meer'
*
Cytokine profiles were studied during 19 episodes of chemotherapy-induced neutropenia in 17 
patients with haematological malignancies. Circulating concentrations of interleukin la  (IL-la), 
tumour necrosis factor a (TNF-a) and 1L-1 receptor antagonist (IL-lra) were measured before 
chemotherapy and thereafter three times weekly. During and after chemotherapy no significant 
changes were found in circulating cytokines. After start of chemotherapy, the ex-vivo 
LPS-stimuIated production of cytokines in whole blood decreased and subsequently disappeared 
completely in all patients, and recovered after the end of treatment. The decrease of cytokine 
production could not be attributed to the decreased number of cells only, as the net production 
per circulating neutrophil or monocyte also decreased significantly, and was restored after 
completion of chemotherapy. These results show that the production of IL-lp, TNF-a and IL-lra  
in blood disappears during chemotherapy-induced neutropenia, not only due to the decreased 
number of producing cells, but also as a result of a decreased production per cell, suggesting 
a mechanism of downregulation.
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Interleukin lß (IL-1 ß) and tumour necrosis 
factor-a (TNF-a) are pro-inflammatory cytokines 
which play an important role in inflammation and 
fever-related processes.1,2 These cytokines are central 
mediators in the pathogenesis of sepsis and septic 
shock.- Interleukin 1 receptor antagonist (IL-lra) is 
also produced early in the course of infection,2 and as 
an inhibitor of the effects of IL-1 it plays an important 
role in the normal and pathological activities of IL-1.4
Neutropenic patients are severely immuno­
compromised and are particularly prone to infections, 
these being the major cause of death in those patients
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as established during autopsy.5 In granulocytopenic 
patients with fever, an infection can be demonstrated 
in about 50%.6 Serum concentrations of TNF, IL-1 
and IL-6 have been found elevated in neutropenic 
children with fever, but no correlation could be 
found with a documented bacterial aetiology.7 In 
another study, serum concentrations of TNF decreased 
during chemotherapy-induced neutropenia and in­
creased when patients developed a bacterial infection.8 
In order to enable proper interpretation of cytokine 
patterns during infections, data are needed about 
the cytokine response to anticancer chemotherapy 
and neutropenia itself. It may be hypothesized that 
leukopenia may lead to reduced production of 
cytokines due to the reduced number of cytokine-pro­
ducing cells. Alternatively, regulatory mechanisms may 
lead to enhanced production of pro-inflammatory 
cytokines during leukopenia, in view of their role 
in haematopoiesis. Studies in mice have shown 
that concentrations of circulating TNF and IL-6 are 
considerably higher in granulocytopenic mice infected 
with Candida albicans than in normal mice,9'10 but 
the cellular source of these cytokines is unknown. 
Little information exists about cytokine profiles of 
pro-inflammatory cytokines during neutropenia in 
humans.
702 CYTOKINE, Vol. 9, No. 9 (September), 1997: pp 702-710
TABLE 1. Patient characteristics.
Patient Age Chemotherapy and Duration of Duration of
No. (year)/sex Diagnosis Clinical status duration (days) Co-medication Infection neutropenia (d) follow up (d)
1 71/F AML 1st relapse ARA-C
DAU
1-7
1
no no 14 17
2 51/F AML newly diagnosed ARA-C
DAU
1-6
4—6
Prednisone 
day 5-9
no 9 18
3 21/M AML 1st relapse ARA-C
IDA
1-5 & 6-15 
2 +  4 +  6
no 1) Staphylococcus epiclermidis septicaemia
2) Aspergillus pneumonia
42 37
4 50/F AML 1st complete 
remission
ARA-C
IDA
1-4
1-4
no no 19 30
5 38/M AML newly diagnosed ETO
CYT
IDA
1-5 
1 & 1-10 
1 + 3  +  5
no 1) Staphlococcus aureus lymphadenitis
2) Pseudomonas aeruginosa malignant otitis 
externa
* 36
6 19/F AML 1st relapse ARA-C
IDA
1-5 & 6-15 
1 + 3  +  5
Prednisone 
day 7-15
1) Pseudomonas aeruginosa mucositis
2) Staphylococcus epidermidis septicaemia
60 36
7 50/M AML newly diagnosed ETO
CYT
IDA
1-5 
1 & 1-10 
1 + 3  +  5
no no 27 30
8 26/M NHL 1st complete 
remission
CFM
MTX
ARA-C
1
1
2-7
no no 19 11
9 46/M NHL 1st relapse ARA-C
MIT
1-6
5-7
G-CSF
day 8
no 17 10
2nd complete CFM 1 G-CSF Streptococcus oralis septicaemia 14 31
remission MTX
ARA-C
1
2-7
day 10 •
10 27/F NHL 2nd complete 
remission
CAR
ETO
ARA-C
MEL
1
2-5
2-5
6
no no 12
•
50
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CFM 1-4 Prednisone Enterococcus urinary tract infection 6 29
ARA-C 1-4 day —4/ — 1
ASP 5-8
ARA-C 1-5 Solumedrol no 10 18
MIT 4-6 day 1-3
CFM 1 + 8 Prednisone no 9 25
DAU 1-3 day 1-22
VIN 1 + 8 + 1 5  + 22
MTX 1 + 8 + 1 5  + 22
CFM 1 +  8 Prednisone no * 12
DAU 1-3 day 1-23
VIN 1 + 8 + 1 5  + 22
MTX 5 + 1 2 + 1 9  + 26
IDA 1-2 no Streptococcus mit is septicaemia 50 36
CFM 11-12
TBI 7 + 8
IDA 1 + 3  + 5 no Clostridium septicum septicaemia 15 47
ARA-C 1-10
ETO 1-5
LEU 1-7 no no t  4 9
CAR 1 no Staphylococcus epidermidis septicaemia 16 37
ETO 2-5
ARA-C 2-5
MEL 6
11
12
13
14
15
16
17
26/F
29/M
21/F
27/M
39/M
38/M
22/M
NHL
NHL
ALL
AUL
RAEB-t
HCL
HL
refractory
refractory
refractory
newly diagnosed
1st complete 
remission
newly diagnosed
1st relapse 
2nd complete 
remission
*Neutropenia was present at the time of diagnosis. 
tPM N  not below 0.5 x 10^ /1 during the follow-up period.
M. male; F, female; NHL, non-Hodgkin’s lymphoma; AML, acute myelogenous leukaemia; ALL. acute lymphocytic leukaemia; HCL, hairy cell leukaemia; AUL. acute undifferentiated leukaemia; RAEB-t. refractory anaemia 
with excess of blasts in transmission; HL, Hodgkin's lymphoma; CFM, cyclophosphamide; MTX, methotrexate; ARA-C, cytosine arabinoside; MIT. mitoxantron; DAU, daunorubicin; VIN. vincristine; CAR, carmustin; 
ETO, etoposidc; MEL, melfalan; ASP, asparaginase; IDA, idarubicine; LEU, leustatin; CYT, cytarabine; TBI, total body irradiation.
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Human cytokine production is usually studied 
in vitro using peripheral blood mononuclear cells 
(PBMC). However, not only PBMC are known to be 
cytokine producing cells, but also neutrophils produce 
IL-lra" and, although to a far less extent than 
monocytes, IL-1.12 The latter is also synthesized by 
many other cell lineages than leukocytes.13 Therefore, 
we investigated the production capacity of IL-lß, 
TNF-a and IL-lra in whole blood in patients 
with haematological malignancies at various stages of 
chemotherapy and neutropenia in the absence of 
infection.
R E S U L T S
Patient characteristics
The clinical characteristics of the patients are 
presented in Table 1. A variety of chemotherapy 
regimens was given for haematological disorders. 
The median duration of chemotherapy treatment was
7 days (range 4 to 26 days) with a median patient 
follow-up period of 30 days (range 9 to 50 days) 
and a median follow-up period after the end of the 
chemotherapy of 21 days (range 0 to 44 days). The 
median duration of neutropenia was 15.5 days (range
6 to 60 days). Two patients (patients 5 and 13) were 
already neutropenic before start of the chemotherapy 
and the neutrophil count of patient 16 remained above 
0.5 X 109/1 during the follow-up period. Five patients 
received systemic corticosteroids as part of their 
chemotherapy regimen and one patient (patient 11) 
finished corticosteroid treatment just before start of the 
chemotherapy. Granulocyte colony-stimulating factor 
(G-CSF) was given in two episodes immediately after 
the end of the chemotherapy. Patients 10, 14 and 17 
received high-dose preparative treatment for sub­
sequent autologous stem cell transplantation. Eight 
patients developed a microbiologically proven infection 
during their hospital stay. In six of these patients, the 
diagnosis of septicaemia was established by positive 
blood cultures.
Circulating cytokines
Before chemotherapy, circulating IL-lß con­
centrations in non-neutropenic patients were higher 
than in healthy controls (P < 0.002). TNF-a and 
IL-lra in the circulation did not differ from controls 
(Table 2).
During and after chemotherapy, no significant 
changes in the circulating concentrations of cytokines 
were found for IL-lß, TNF-a or IL-lra (data not 
shown). Neither treatment with corticosteroids or 
G-CSF nor the presence of infection had an effect 
on concentrations of circulating cytokines (stepwise 
regression analysis; data not shown).
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TA BLE 2. Cytokines before chemotherapy.
Patients Controls
(/! = 17) (n = 20)
Circulating cytokines (pg/ml)
IL-lß 74 ± 33* 44 ± 1 0
TNF-a 94 ± 20 92 ± 1 7
IL-lra 298 ±138 237 ± 92
LPS-stimulated cytokine production ex vivo (pg/ml)
IL-lß 10 982 ± 7374 7635 ± 3509
TNF-a 5008 ± 2261 6804 ± 2249
IL-lra 8290 ± 2465| 12 342 ± 3374
Results are expressed as mean ±  s tandard  deviation.
*Significantly higher in patients than in controls  (P <  0.002). 
tSignificantly lower in patients than in controls  (P <  0.001).
Ex-vivo cytokine production
Before chemotherapy, the non-neutropenic 
patients showed a significantly lower ex-vivo IL-lra 
production compared to healthy controls (P < 0.001). 
No difference was detected for IL-lß or TNF-a 
(Table 2). In the two patients who were already 
neutropenic before chemotherapy, the ex-vivo pro­
duction of all cytokines tested was extremely low 
(<500 pg/ml). In all patients the net ex-vivo pro­
duction of the three cytokines decreased below 
500 pg/ml and successively disappeared completely 
after chemotherapy was started. Production of 
cytokines increased again after end of treatment, upon 
neutrophil recovery (Fig. 1). This pattern was not 
influenced by administration of G-CSF or corticos­
teroids, and there was no significant difference between 
patients with or without infections (stepwise regression 
analysis; data not shown). Cytokine production 
decreased below 500 pg/ml after a median of 4.5 days 
(range 1-12 days) for IL-lß, 3.5 days (1-11 days) for 
TNF-a and 10 days (4-15 days) for IL-lra. For the 
cytokines studied, a net production of more than 
500 pg/ml was regained after a median duration of 15 
days after completion of chemotherapy, with a range 
of 0-24 days for IL-1 lß and TNF-a, and 0-21 days for 
IL-lra. In only one patient the cytokine production 
was restored before the whole chemotherapy cycle was 
finished.
Ex-vivo cytokine production expressed per cell
In order to assess whether the observed reduction 
of ex-vivo cytokine production is solely due to a 
decrease of the number of cytokine-producing cells, 
the net production capacity measured in whole blood 
was expressed per neutrophil and per monocyte, 
respectively. To normalize for the wide variation in 
neutrophil number among our patients, Figures 2 
and 3 depict the time course of the net cytokine 
production capacity, with numbers of PMN normal­
ized by expressing the PMN count in terms of 
percentage of the initial count before chemotherapy.
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Figure 1. LPS-stimulated net ex-vivo production of IL-lß , T N F-a  
and IL-lra in whole blood before, during and after chemotherapy in 
17 patients treated with anticancer chemotherapy (mean +  SEM ).
Significant differences between consecutive time points are indicated 
(*P < 0.05),
Interestingly, the production of all three cytokines 
measured decreased rapidly before the number of 
circulating cells began to decrease. Most notably, this 
decreased production was even observed in those 
patients who showed an initial increase of the number
of neutrophils after start of chemotherapy. Therefore, 
the cytokine production as expressed per cell was 
significantly decreased after the start of chemotherapy, 
both when expressed per neutrophil (Fig. 2) and per
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Figure 2. LPS-stimulated net ex-vivo production of IL-lß, T N F-a  
and IL-lra in whole blood expressed per neutrophil during consecutive 
stages of anticancer chemotherapy treatment in 17 patients 
(mean ±  SEM ).
I, before chemotherapy: II, PMN remaining > 100% of initial value: 
III, PMN decreasing from 100% to 20% of initial value; IV, PMN 
20-2%: V, PMN 1-0%; VI, PMN increasing from 0% to 10% of 
initial value; VII, PMN 10-50%; VIII, PMN >50% of initial value. 
Significant differences between consecutive time points are indicated 
(*ƒ> < 0.05).
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monocyte (Fig. 3). In contrast, the production of 
IL-lra as expressed per circulating monocyte appeared 
to increase (Fig. 3), although its total production 
decreases significantly upon induction of neutropenia
(Fig. 1).
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Figure 3. LPS-stimulated net ex-vivo production of IL-lß, T N F-a  
and IL-lra in whole blood expressed per monocyte during consecutive 
stages o f anticancer chemotherapy treatment in 17 patients 
(mean ±  SEM ).
I, before chemotherapy; II, PMN remaining > 100% of initial value; 
III, PMN decreasing from 100% to 20% of initial value; IV, PMN 
20-2%; V, PMN 1-0%; VI, PMN increasing from 0% to 10% of 
initial value; VII, PMN 10-50%; VIII, PMN >50% of initial value. 
Significant differences between consecutive time points are indicated 
(*P< 0.05).
During recovery from neutropenia after com­
pletion of the chemotherapy cycle, cytokine production 
was restored, even before the number of cells began to 
rise (Fig. 2). When the ex-vivo cytokine production 
capacity at various PMN counts during induction 
of neutropenia was compared to the production 
at corresponding PMN counts during recovery, 
production of IL-lß, TNF-a and IL-lra during the 
recovery phase was significantly higher than during 
the induction of neutropenia, even though the total 
amount of circulating cells was the same in both groups 
(data not shown).
D I S C U S S I O N
In the present study we investigated cytokine 
profiles in patients with haematological malignancies 
before, during and after chemotherapy in a whole 
blood culture system. Circulating concentrations of 
IL-lß were significantly elevated in these patients 
before treatment, but chemotherapy and induction of 
neutropenia did not influence IL-lß, TNF-a or IL-lra 
concentrations in plasma. The net production of IL-lß, 
TNF-a and IL-lra in whole blood disappeared rapidly 
during chemotherapy, already before induction of 
neutropenia. When expressed per circulating neutro­
phil or monocyte, the cytokine production capacity 
decreased immediately after start of the chemotherapy, 
independently of the number of cells, suggesting a 
mechanism of downregulation of cytokine production 
after chemotherapy. After completion of chemo­
therapy, the net production of the three cytokines 
increased again before the number of cells did, 
probably due to an enhanced production per cell.
The downregulation of cytokine production after 
the start of chemotherapy may be caused by a direct 
cytotoxic effect of the therapy. The finding that the 
decrease of cytokine production capacity occurred 
regardless of the chemotherapy regimen used, suggests 
that the mechanism for this downregulation is not 
specific. The fact that this occurred for all three 
cytokines studied implies a general toxic effect on the 
cell, interfering with various cellular mechanisms. 
Ridgway and Borzy14 have demonstrated that antineo­
plastic treatment for children with acute lymphocytic 
leukaemia (ALL) can damage the mechanisms which 
lead to cytokine production in PBMC. In the present 
study we have shown that the cytokine production 
during the recovery of the neutrophils is significantly 
higher than during the induction of neutropenia, even 
when the number of circulating PMN is similar in both 
phases, which supports the hypothesis that a cytotoxic 
effect plays a role. Alternatively, the rise in cytokine 
production per cell during the recovery phase may be 
accounted for by exposure of circulating cells to other
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cytokines and growth factors that are produced during 
this period of increased haematopoietic activity, such 
as G-CSF.
Our study included two patients with newly 
diagnosed leukaemia who were already neutropenic 
before administration of chemotherapy. The ex-vivo 
production of the three cytokines measured was 
downregulated in these patients at the time of 
inclusion. This suggests that other mechanisms than 
cytotoxic drugs may be responsible for this down­
regulation as well, which in this case could be the 
disease or the neutropenia itself. In our study however, 
there was no difference in cytokine production between 
non-neutropenic cancer patients and healthy controls, 
with the exception of a significant lower ex-vivo pro­
duction of IL-lra in patients. Although the group of 
patients studied is relatively small and quite diverse in 
terms of primary haematological disease, the pattern of 
reduced ex-vivo cytokine production during induction 
of neutropenia was found in all patients studied. These 
observations suggest that the malignant disease itself 
does not severely affect cytokine production. It cannot 
be excluded that neutropenia itself, directly or 
indirectly, may contribute to reduced cytokine pro­
duction. Therefore, it is obvious that further studies 
need to be carried out in patients who are neutropenic 
due to other causes than chemotherapy.
To our knowledge, this study is the first to 
investigate cytokine production during granulocytope­
nia using a whole blood culture system. Whole blood 
can be used as a reliable alternative to PBMC to 
measure cytokine production upon stimulation with 
LPS, providing a simple method that requires minimal 
laboratory facilities and which maintains a physiologi­
cal environment.15,16 PBMC from children treated 
with continuous maintenance therapy for ALL have 
a decreased ability to produce IL-1 and GM-CSF,14 
which is consistent with our observations in whole 
blood. Takamatsu et al. showed that a significant 
increase of IL-lß, IL-6 and G-CSF production by 
monocytes occurs in adults with various haematologi­
cal malignancies during haemopoietic recovery after 
chemotherapy treatment, when compared with normal 
healthy subjects.17
It may be questioned whether the observed 
down-regulation of cytokine production during 
chemotherapy-induced neutropenia is beneficial. It 
could be hypothesized that due to an extremely low 
production of pro-inflammatory cytokines, these 
patients are less prone to develop severe sepsis syn­
drome. However, IL-lra, which is thought to protect 
against lethal sepsis, has also been downregulated. If 
chemotherapy directly affects the ability to produce 
TNF-a and IL-1 then this could, at least partly, explain 
the bone marrow toxicity and the greater risk of 
infections in these patients. Indeed, IL-1 has been
shown to accelerate bone marrow recovery after myelo- 
suppression18 and TNF-a has protective effects on 
haematopoiesis in animals given cycle-specific chemo­
therapy.,y TNF-a also possesses anti-viral activity20 and 
enhances neutrophil function21 and so may be beneficial 
in controlling infections during neutropenia.
Most studies done so far in neutropenic patients 
have only reported on circulating cytokines and have 
not taken into account ex-vivo production capacity. 
Circulating concentrations may represent the cytokines 
available in the bloodstream, but may not provide an 
accurate measurement of cell activation. The LPS- 
stimulated production capacity of circulating cytokine 
producer cells may more accurately reflect the immune 
response, although it has to be considered that these 
cells may not be representative of the behaviour of 
extravasated or adherent cells in local inflammatory 
areas. Whereas the circulating TNF-a concentrations 
in our patients did not differ from those in healthy 
controls, several investigators have found increased 
pretreatment concentrations of serum TNF-a in 
acute myelogenous leukaemia (AML) patients.22,23 This 
difference could possibly be explained by the different 
patient populations, as only AML patients were 
included in those studies. This is supported by the fact 
that in the same study no difference for TNF-a was 
found when the controls were compared to patients 
with Non-Hodgkin’s lymphoma (NHL).22 Others have 
reported a significant decrease of circulating TNF-a 
after chemotherapy in patients with acute leukaemia 
developing neutropenia.8,24 A possible explanation 
could be that in those studies an ELISA was used for 
measurement of TNF-a, whereas we used a RIA which 
also measures circulating TNF-a bound to its soluble 
receptor (sTNFR).
Attempts to correlate circulating cytokine levels 
with fever or proven infections in neutropenic patients 
have been made by many investigators.7,8,25~27 Although 
the aim of the present study was to assess the effect 
of neutropenia and chemotherapy per se on cytokine 
production rather than to study cytokines during 
infection, 6 patients in our study group had proven 
bacteraemia. Although these numbers are too small to 
draw definite conclusions, our data did not show any 
correlation between concentrations of circulating 
cytokines and the presence of an infection.
In conclusion, although no change was found 
in circulating cytokine concentrations, ex-vivo pro­
duction of IL-lß, TNF-a and IL-lra in whole blood 
disappeared rapidly after start of chemotherapy. 
This effect is not only due to the decreased number of 
producing cells, but is also a result of a decreased 
production per cell. This suggests a mechanism 
of downregulation of cytokine production during 
chemotherapy-induced neutropenia, most likely due to 
a cytotoxic effect of chemotherapy.
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M ATERIALS AND M E T H O D S
Study protocol
Consecutive inpatients with leukaemia or m alignant 
lym phom a who were eligible for chem otherapy were enrolled. 
Over a 4-m onth period 19 neutropenic episodes in 17 patients 
(10 men and 7 women) with a m edian age o f 29 years (range
19 to 71 years) were studied. N eutropenia  was defined as 
< 0 .5  X 109 po lym orphonuclear cells (PMN)/1. Twenty 
healthy volunteers (5 men, 15 women; median age 44.5 years; 
range 19 to 62 years) served as norm al controls.
Blood was draw n once before the start o f  chem otherapy 
and thereafter three times weekly during the hospital stay 
and when possible also after discharge during visits at 
the ou tpatien t clinic. F o r collection o f cytokines special 
endotoxin-free tubes containing 48 |il o f  E D T A  were used 
(Vacutainer Systems; Becton Dickinson, R utherford , NJ). 
The plasma o f  one tube was immediately processed to avoid 
ex-vivo cytokine induction .28 This tube was centrifuged at 
2250 X g  for 10 min and then at 20 000 x g  for 5 min to 
obtain platelet-poor plasma. The supernatants were stored at 
— 20 C until analysis for circulating cytokines. Ex-vivo 
cytokine production was measured using a whole blood 
culture system as described earlier .29 Briefly, 4 ml o f  blood 
was incubated with or w ithout 50 jil o f  lipopolysaccharide 
(LPS; Escherichia coli serotype 055:B5, final concentration
10 jig/ml; Sigma, St Louis, MO). After 24 h o f  incubation at 
37°C the blood was centrifuged as described above and 
plasma was collected and stored at — 20°C until assayed for 
cytokines. Leukocyte num bers and differential counts were 
determined with an au tom ated  H3 counter (Bayer Technicon 
M ijdrecht, The Netherlands).
Cytokine assays
C oncentrations o f IL -lß , T N F -a  and IL - lra  were 
determined in plasma and measured in duplicate by 
radioim m unoassay (RIA ) as described earlier .30 The sensi­
tivity o f  the assay with 100 |,U sample for circulating cytokine 
m easurem ent was 20 pg/ml (T N F-a), 40 pg/ml (IL -lß )  and 
60 pg/ml (IL -lra ). F o r measurements o f  ex-vivo production, 
25 ja1 (T N F -a) or 10j.il ( IL -lß  and IL -lra )  o f  sample were 
used in the RIA; the sensitivity of these measurements was 
80 pg/ml for T N F -a , 40 pg/ml for IL -lß  and 600 pg/ml for 
IL -lra . The net cytokine production capacity was expressed 
as cytokine contents after LPS-stimulated incubation minus 
contents after incubation w ithout LPS.
Statistical analysis
Statistical com parisons were performed using the 
M ann-W hitney  U test or the 2-sided Student /-test. The 
relationship between circulating cytokines or net cytokine 
production and num ber o f  neutrophils, presence o f infection 
and medication was assessed by stepwise regression analysis. 
Statistical significance was defined as P < 0.05.
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